Have a personal or library account? Click to login
Immunotherapy-Induced Acute Hepatitis in the Elderly: The Case of a Patient with Urothelial Carcinoma and a Review of the Literature Cover

Immunotherapy-Induced Acute Hepatitis in the Elderly: The Case of a Patient with Urothelial Carcinoma and a Review of the Literature

Forum of Clinical Oncology
Volume 12 (2021): Issue 3 (December 2021)
By:
Open Access
|Feb 2022

Figures & Tables

Figure 1

Abdominal CT performed during hospitalization.
Abdominal CT performed during hospitalization.

Figure 2

ALT, AST, and blood bilirubin levels during hospitalisation.
ALT, AST, and blood bilirubin levels during hospitalisation.

Common terminology criteria for adverse hepatic immune-mediate adverse events[24]_

GRADE 1GRADE 2GRADE 3GRADE 4
ALT>ULN – 3.0×ULN>3.0–5.0 × ULN>5.0–20.0×ULN>20.0 ×ULN
AST>ULN – 3.0×ULN>3.0–5.0 × ULN>5.0–20.0×ULN>20.0 ×ULN
Blood Bilirubin>ULN – 1.5×ULN>1.5–3.0 × ULN>3.0–10.0×ULN>10.0×ULN
DOI: https://doi.org/10.2478/fco-2021-0003 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 28 - 33
Submitted on: Apr 11, 2021
Accepted on: Jul 15, 2021
Published on: Feb 1, 2022
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
Immunotherapy-related adverse events,
pembrolizumab,
immunotherapy-related hepatitis,
elderly
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2022 Ioannou Alexandros, Papaxoinis Georgios, Dimitroulopoulos Dimitrios, Tryfonopoulos Dimitrios, Gouveris Panagiotis, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 12 (2021): Issue 3 (December 2021)Next article